


CLAIMS

1. A compound of formula (I):

5



10

(I)

wherein:

X is C₁₋₆ alkylene or C₂₋₆ alkenylene, each of which is optionally substituted by one or more
15 fluorine atoms;

R is aryl or C₃₋₈ cycloalkyl optionally substituted by one or more fluorine atoms;

W is N or CZ;

20

Y is

- (a) NR¹R³,
 (b) C₁₋₄ alkyl substituted by NR¹R² or by a 4- to 7-membered N-heterocycle attached via the N-
 atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently
 25 selected from N, O and S, and which heterocycle is optionally substituted by one or more
 substituents independently selected from R², =O and OH,
 or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which
 heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N,
 O and S, and which heterocycle is optionally substituted by one or more substituents
 30 independently selected from R², =O and OH,

Z is H or C₁₋₄ alkyl,

or when W is CZ, Y can be H or C₁₋₄ alkyl, and Z can be

35

- (a) NR¹R³,
 (b) C₁₋₄ alkyl substituted by NR¹R² or by a 4- to 7-membered N-heterocycle attached via the N-
 atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently
 selected from N, O and S, and which heterocycle is optionally substituted by one or more
 substituents independently selected from R², =O and OH,

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

5

R^2 is H,

C_{1-6} alkyl (optionally substituted by one or more substituents independently selected from OH, C_{1-4} alkoxy, $C(O)_p(C_{1-4}$ alkyl, aryl, heteroaryl, or NR^1R^3), $CONR^1R^3$ or NR^1R^3), $SO_2(C_{1-4}$ alkyl, aryl, heteroaryl or NR^1R^3),

10 $C(O)_p(C_{1-4}$ alkyl optionally substituted by C_{1-4} alkoxy or NR^1R^3),

$C(O)_p(C_{3-7}$ cycloalkyl),

$C(O)_p(aryl)$,

$C(O)_p(heteroaryl)$,

$CONR^1R^3$,

15 C_{3-7} cycloalkyl optionally substituted by one or more substituents independently selected from OH and C_{1-4} alkoxy,

a 4- to 7-membered saturated or partially or fully unsaturated heterocycle, which heterocycle ring contains up to 3 ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from

20 R^3 , =O, OH, $SO_2(C_{1-4}$ alkyl) and/or $C(O)_p(C_{1-4}$ alkyl) groups,

or aryl,

R^1 and R^3 are each independently selected from H and (C_{1-4} alkyl optionally substituted by OH, NR^4R^5 or by C_{1-4} alkoxy),

25

R^4 and R^5 are each independently selected from H and C_{1-4} alkyl,

p is 1 or 2,


30 "aryl" is phenyl optionally substituted by one or more substituents independently selected from R^3 , OH, $SO_2(C_{1-4}$ alkyl) and/or $C(O)_p(C_{1-4}$ alkyl) groups,

"heteroaryl" is a 5- to 7-membered aromatic heterocycle with 1, 2 or 3 ring hetero-atoms independently selected from N, O and S, and which ring is optionally substituted by one or more substituents independently selected from R^3 , =O, OH, $SO_2(C_{1-4}$ alkyl) and/or $C(O)_p(C_{1-4}$ alkyl) groups,

35

and the pharmaceutically acceptable salts, solvates (including hydrates) and prodrugs thereof.

2. A compound, salt, solvate or prodrug according to claim 1 wherein the compound of formula (I) has the following stereochemistry (IA):



10 (IA)

3. A compound, salt, solvate or prodrug according to claim 1 wherein W is N.

15 4. A compound, salt, solvate or prodrug according to claim 1 wherein X is a linear C₂₋₆ alkylene moiety optionally substituted by one or more fluorine atoms.

5. A compound, salt, solvate or prodrug according to claim 1 wherein R is C₃₋₈ cycloalkyl optionally substituted by one or more fluorine atoms.

20

6. A compound, salt, solvate or prodrug according to claim 1 wherein Y is C₁₋₄ alkyl substituted by NR¹R², or Y is a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R², =O and OH.

25

7. A compound, salt, solvate or prodrug according to claim 1 wherein W is CZ and Z is H or CH₃.

8. A compound, salt, solvate or prodrug according to claim 1 wherein X is propylene.

30

9. A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclobutyl, cyclopentyl or cyclohexyl optionally substituted by one or more fluorine atoms.

10. A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH₂ substituted by NR¹R², or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by one or more substituents independently selected from R², =O and OH.

35

11. A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclohexyl.

12. A compound, salt, solvate or prodrug according to claim 1 wherein Y is $\text{CH}_2\text{N}(\text{H or CH}_3)(\text{SO}_2(\text{C}_{1-4} \text{ alkyl, aryl, heteroaryl or NR}^1\text{R}^3))$, or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by $\text{SO}_2(\text{C}_{1-4}$ alkyl) and/or $\text{C}(\text{O})_p(\text{C}_{1-4} \text{ alkyl})$ groups.
13. A compound, salt, solvate or prodrug according to claim 1 wherein Y is $\text{CH}_2\text{NHSO}_2(\text{C}_{1-4} \text{ alkyl})$, or Y is a 6-membered saturated N-heterocycle, and which heterocycle is optionally substituted by $\text{SO}_2(\text{C}_{1-4} \text{ alkyl})$ or $\text{C}(\text{O})_p(\text{C}_{1-4} \text{ alkyl})$.
14. A compound, salt, solvate or prodrug according to claim 1 wherein Y is $\text{CH}_2\text{NHSO}_2\text{CH}_3$ or methylsulphonylpiperidinyl.
15. A compound selected from any of the Examples disclosed herein, or a salt, solvate or prodrug thereof.
16. A pharmaceutical composition comprising a compound, salt, solvate or prodrug according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.
17. A kit comprising :
a compound, salt, solvate or prodrug according to claim 1, packaging; and instructions for the use of the said compound, salt, solvate, prodrug or composition in a manner suitable for treating or preventing a condition mediated by PCP.
18. A compound, salt, solvate or prodrug according to of claim 1 for use in treating or preventing a condition mediated by PCP.
19. A method of treating or preventing a condition mediated by PCP which comprises administration of an effective amount of a compound, salt, solvate or prodrug according to claim 1 to a patient in need thereof.